may
conven
meet
work
group
technic
specif
manufactur
evalu
yellow
fever
yf
vaccin
geneva
switzerland
initi
revis
recommend
formerli
requir
yf
vaccin
publish
technic
report
seri
number
work
group
consist
expert
academia
industri
nation
regulatori
author
nation
control
laboratori
review
latest
issu
safeti
efficaci
qualiti
yf
vaccin
agre
revis
focu
live
attenu
yf
vaccin
viru
lineag
ii
nonclin
clinic
guidelin
new
vaccin
prepar
lineag
develop
dr
david
wood
coordin
qualiti
safeti
standard
qss
team
world
health
organ
welcom
particip
meet
remind
yellow
fever
yf
diseas
major
public
health
import
africa
south
america
still
outbreak
recent
paraguay
countri
risk
vaccin
assur
qualiti
essenti
routin
immun
mass
campaign
emphas
import
consult
view
advers
event
includ
yellow
fever
vaccineassoci
neurolog
diseas
yeland
yellow
fever
vaccineassoci
viscerotrop
diseas
yelavd
occur
past
year
cluster
advers
event
occur
mass
vaccin
campaign
peru
expert
panel
conven
investig
report
found
link
vaccin
product
lot
howev
recommend
guidelin
yf
vaccin
review
year
sinc
publish
dr
wood
also
inform
group
yf
vaccin
import
regul
intern
travel
diseas
certif
vaccin
requir
entri
countri
updat
intern
health
regul
ihr
increas
attent
need
certif
yf
vaccin
gone
approv
process
establish
publish
list
vaccin
list
therefor
need
go
approv
process
use
context
ihr
current
recommend
formerli
requir
yf
vaccin
adopt
publish
disclaim
report
contain
collect
view
intern
group
expert
necessarili
repres
decis
state
polici
world
health
organ
mention
specif
compani
certain
manufactur
product
impli
endors
recommend
world
health
organ
prefer
other
similar
natur
mention
technic
report
seri
tr
work
group
look
current
specif
see
need
chang
dr
ivana
knezev
qsswho
present
updat
biolog
standard
posit
discuss
term
work
qss
issu
import
area
yf
vaccin
activ
qss
group
within
includ
ensur
vaccin
assur
qualiti
regulatori
guidanc
implement
new
standard
goal
immun
programm
includ
increas
sustain
vaccin
coverag
reduc
morbid
mortal
use
vaccin
assur
qualiti
introduc
new
vaccin
vaccin
new
manufactur
modifi
vaccin
product
strengthen
nation
regulatori
author
nra
also
import
nra
function
form
essenti
part
qualiti
assur
vaccin
expert
committe
biolog
standard
ecb
play
essenti
role
norm
function
eg
establish
standard
written
physic
written
standard
produc
form
guidelin
recommend
use
regul
vaccin
worldwid
also
prequalif
vaccin
establish
written
standard
must
evidencebas
expert
field
provid
evid
written
standard
includ
nonclin
clinic
issu
work
ecb
support
expert
advisori
panel
collabor
centr
includ
intern
laboratori
biolog
standard
nation
institut
biolog
standard
control
nibsc
paulehrlichinstitut
pei
center
biolog
evalu
research
cber
us
food
drug
administr
fda
key
issu
stimul
revis
recommend
yf
vaccin
implement
new
potenc
specif
intern
unit
iu
ii
avail
molecular
method
applic
detect
microbi
agent
test
ident
iii
need
review
updat
necessari
establish
safeti
test
guid
principl
clinic
nonclin
evalu
efficaci
endpoint
doserang
studi
clinic
minimum
potenc
iu
safeti
consider
standard
fulli
adopt
nra
implement
nation
regul
implement
manufactur
procedur
consid
nation
pharmacopoeia
appropri
incorpor
gener
specif
monograph
dr
knezev
inform
tr
annex
guidelin
cell
substrat
revis
new
cellbas
yf
vaccin
develop
revis
yf
recommend
read
conjunct
discuss
dr
minor
ask
whether
manufactur
research
group
plan
develop
yf
vaccin
vero
cell
histor
cell
cultur
method
found
suitabl
use
routin
product
term
qualiti
product
indic
case
group
agre
scope
discuss
limit
embryon
chicken
eggbas
product
dr
jinho
shin
qsswho
present
object
expect
outcom
meet
ecb
endors
propos
updat
entir
document
recommend
yf
vaccin
upon
note
key
issu
describ
dr
knezev
acknowledg
express
yf
vaccin
potenc
iu
great
achiev
two
decad
intern
collabor
effort
first
case
live
vaccin
first
collabor
studi
yf
vaccin
potenc
undertaken
earli
use
common
prepar
improv
reproduc
result
potenc
test
laboratori
find
readdress
twenti
year
later
intern
standard
yf
vaccin
use
potenc
test
establish
object
may
consult
initi
revis
recommend
yf
vaccin
publish
tr
ii
discuss
scientif
basi
set
manufactur
qualiti
control
specif
yf
vaccin
iii
develop
regulatori
expect
evalu
nonclin
clinic
studi
yf
vaccin
discuss
dr
barrett
highlight
controversi
issu
propos
scientist
involv
product
regul
vaccin
name
sequenc
everi
batch
dr
minor
agre
would
address
nonclin
test
crucial
even
though
yf
vaccin
oldest
live
viral
vaccin
market
success
dr
gill
poumerol
ihrwho
updat
group
ihr
yf
ihr
first
issu
updat
approv
member
state
implement
june
sever
acut
respiratori
syndrom
sar
outbreak
stimul
revis
ensur
health
secur
minim
interfer
health
trade
billion
air
travel
year
issu
one
area
world
affect
entir
world
regul
comprehens
use
regul
consider
chang
previou
version
includ
chang
control
border
contain
sourc
ii
chang
diseas
list
public
health
threat
iii
chang
preset
measur
adapt
respons
nation
ihr
focal
point
state
ihr
contact
point
inform
may
obtain
exchang
rapid
exchang
inform
current
outbreak
influenza
would
good
exampl
system
work
yf
diseas
specif
cite
ihr
requir
certif
vaccin
access
countri
vaccin
use
must
suitabl
qualiti
approv
presum
prequalif
process
exist
mechan
evalu
qualiti
vaccin
suppli
countri
mainli
mass
vaccin
purpos
vaccin
shall
administ
design
vaccin
centr
specif
vaccin
certif
issu
ihr
requir
share
inform
global
seriou
public
health
event
risk
map
yf
articl
annex
vaccin
centr
subject
nation
regul
intern
certif
vaccin
contraind
sign
physician
dissemin
key
public
health
inform
crucial
must
send
relev
inform
soon
possibl
enabl
member
state
respond
public
health
risk
yf
risk
map
vaccin
recommend
detail
updat
public
intern
travel
health
map
area
risk
indic
low
medium
high
risk
new
revis
recommend
yf
vaccin
low
risk
area
countri
fall
group
constant
review
enceph
report
follow
vaccin
infant
month
age
albeit
rare
event
result
vaccin
contraind
children
age
month
recommend
age
month
websit
intern
travel
health
prove
success
hit
per
week
includ
interact
map
provid
inform
recommend
yf
vaccin
malaria
prophylaxi
yf
expert
group
advis
practic
criteria
defin
area
vaccin
recommend
visitor
areascountri
risk
yf
transmiss
trigger
potenti
certif
requir
dr
rosamund
lewi
epidem
readi
intervent
team
remind
group
histori
yf
endem
us
europ
zone
transmiss
south
america
africa
centuri
yf
declin
dramat
africa
follow
number
mass
vaccin
campaign
decreas
number
case
yf
success
vaccin
result
lack
interest
yf
surveil
consequ
immun
progress
neglect
yf
reappear
late
mani
african
countri
outbreak
occur
recur
period
depend
geograph
locat
frequent
outbreak
west
africa
outbreak
often
separ
year
south
america
rare
outbreak
east
africa
yellow
fever
initi
partnership
work
prevent
yellow
fever
epidem
across
africa
latin
america
prevent
vaccin
emerg
respons
object
yellow
fever
initi
secur
vaccin
product
capac
vaccin
peopl
high
risk
boost
popul
immun
stockpil
million
dose
establish
emerg
respons
capabl
although
routin
vaccin
suppli
may
divert
emerg
respons
requir
vaccin
suppli
unit
nation
children
fund
unicef
prequalifi
produc
vaccin
prequalifi
procur
vaccin
use
replac
annual
addit
emerg
respons
routin
infant
immun
prevent
vaccin
campaign
implement
popul
highest
risk
routin
immun
children
immun
month
age
africa
month
brazil
month
america
africa
booster
offer
prevent
campaign
serv
catchup
vaccin
unreach
routin
programm
brazil
booster
mandatori
year
endem
area
countri
level
risk
assess
perform
consid
histori
case
presenc
vector
popul
immun
recent
vaccin
select
district
highest
risk
fund
support
includ
million
dollar
global
allianc
vaccin
immunis
gavi
fund
european
commiss
humanitarian
aid
echo
emerg
respons
fund
eu
surveil
vaccin
strategi
adapt
countri
need
vaccin
suppli
vaccin
demand
risen
million
dose
million
dose
period
theoret
vaccin
suppli
tripl
million
million
dose
product
million
dose
due
present
select
fewer
vial
surveil
advers
event
follow
immun
aefi
also
undertaken
prevent
mass
campaign
countri
also
establish
regular
system
continu
surveil
aefi
suspect
seriou
aefi
case
report
per
person
vaccin
togo
seneg
mali
howev
case
seriou
aefi
yet
classifi
confirm
death
virolog
studi
undertaken
countri
dr
lewi
indic
obtain
sampl
potenti
aefi
complex
improv
experi
dr
reinaldo
martin
biomanguinho
ad
sampl
collect
problemat
brazil
improv
use
collect
kit
blood
sampl
dr
alan
barrett
utmb
univers
texa
medic
branch
summar
outcom
workshop
world
congress
medicin
health
tropic
held
marseil
franc
workshop
yf
epidemiolog
vaccin
vaccin
discuss
time
meet
outbreak
yf
trinidad
outbreak
paraguay
earli
provid
evid
urban
yf
first
time
sinc
antivir
drug
flaviviru
infect
includ
yf
avail
vaccin
import
resid
popul
travel
risk
vaccin
recipi
low
current
avail
data
suggest
rare
case
yelavd
relat
individu
genet
determin
current
unknown
host
factor
regul
cellular
suscept
attenu
yf
viru
rather
revers
vaccin
viru
virul
phenotyp
molecular
anim
studi
perform
date
provid
evid
mutat
vaccin
viru
contribut
yelavd
cluster
case
viscerotrop
diseas
occur
ica
peru
four
recipi
lot
vaccin
die
howev
geograph
dispers
subject
make
unlik
relat
genet
background
viru
isol
individu
sequenc
found
vaccin
viru
evid
mutat
conclus
extens
investig
advers
event
observ
vaccin
batchrel
productionrel
even
though
vaccin
viru
caus
diseas
differ
lot
vaccin
suggest
must
cofactor
lead
diseas
immun
respons
induc
viru
investig
larg
number
studi
neutral
antibodi
correl
protect
although
actual
mechan
protect
known
recent
studi
investig
immun
respons
induc
vaccin
includ
studi
b
cell
assay
neutral
antibodi
still
gold
standard
intern
recogn
protect
neutral
antibodi
titr
querec
et
al
identifi
predictor
tcell
respons
encod
receptor
growth
factor
blysbaff
predictor
neutral
antibodi
respons
induc
vaccin
although
studi
cytokin
help
understand
advers
event
contribut
qualiti
control
vaccin
seriou
aefi
follow
yf
immun
poorli
understood
although
advanc
understand
immun
respons
induc
vaccin
may
help
elucid
mechan
mani
paper
publish
advers
event
mechan
death
viscerotrop
diseas
unknown
comprehens
studi
fatal
yelavd
young
femal
patient
unit
state
identifi
heterozyg
genet
polymorph
chemokin
receptor
ligand
rant
dcsign
wildtyp
potenti
hypothesi
centr
disconnect
signal
innat
immun
respons
time
activ
adapt
immun
respons
follow
cluster
advers
event
observ
ica
peru
suggest
mainli
physician
viru
genom
sequenc
lot
vaccin
howev
unlik
help
sequenc
deal
major
popul
heterogen
necessarili
detect
much
weight
current
place
monkey
studi
investig
altern
anim
model
hamster
model
develop
utmb
instituto
evandro
chaga
iec
brazil
show
viscerotrop
diseas
howev
wildtyp
strain
need
adapt
hamster
virus
yelavd
case
show
viscerotrop
diseas
model
new
small
anim
model
nonadapt
wildtyp
yfv
show
viscerotrop
diseas
said
show
promis
publish
subsequ
meet
molecular
basi
attenu
investig
compar
known
sequenc
wildtyp
asibi
viru
attenu
vaccin
deriv
date
mechan
attenu
elucid
mous
model
indic
multigen
caus
attenu
neurotrop
noth
known
basi
attenu
viscerotrop
either
nonhuman
primat
hamster
model
structur
inform
may
use
nonclin
studi
shown
dengu
viru
neutral
epitop
surfac
critic
virul
genotyp
dr
adwoa
bentsienchil
qsswho
report
recent
review
yf
vaccin
safeti
data
discuss
global
advisori
committe
vaccin
safeti
gacv
seriou
ae
includ
hypersensit
anaphylaxi
yelavd
yeland
risk
factor
either
known
potenti
vaccin
includ
age
compromis
immun
includ
hivaid
pregnanc
nonadher
indic
use
gacv
undertook
risk
benefit
consider
endem
nonendem
popul
obtain
inform
prequalifi
manufactur
relat
viscerotrop
nonviscerotrop
diseas
risk
factor
identifi
estim
could
made
issu
relat
incid
peru
review
detail
first
report
yelavd
publish
past
eight
year
sever
incid
frequenc
hard
determin
accur
low
ii
difficult
obtain
reliabl
figur
number
dose
use
countri
iii
figur
may
affect
popul
relat
factor
includ
exposur
flavivirus
gener
estim
rang
per
brazil
travel
nonendem
area
differ
incid
endem
region
versu
popul
probabl
relat
popul
differ
previou
vaccin
exposur
wild
viru
ica
peru
incid
fatal
case
yelavd
observ
recipi
singl
lot
vaccin
lot
confirm
virolog
clinic
give
rate
yelavd
per
lot
vaccin
extens
investig
undertaken
region
offic
america
amro
headquart
expert
panel
conven
assist
peruvian
govern
visit
manufactur
site
reveal
qualiti
issu
character
secondari
seed
batch
record
satisfactori
report
problem
batch
prepar
final
bulk
lot
caus
problem
potenc
data
avail
variou
laboratori
sampl
batch
use
releas
end
shelf
life
recov
field
although
potenc
differ
laboratori
directli
compar
methodolog
use
differ
vaccin
lot
retain
potenc
even
though
move
around
south
america
prior
use
peru
addit
result
potenc
test
indic
indistinguish
sister
lot
vaccin
associ
yelavd
result
potenc
test
lot
therefor
gave
explan
higher
frequenc
viscerotrop
diseas
batch
incid
remain
unexplain
case
clearli
vaccin
associ
extens
studi
vaccin
reveal
featur
would
account
bulk
use
batch
gave
problem
noth
specif
batch
exampl
high
titr
distinguish
batch
account
investig
publish
subsequ
meet
incid
yelavd
time
higher
previous
report
vaccin
caus
death
appear
overwhelm
diseas
caus
strain
possibl
associ
host
immun
respons
vaccin
viru
vial
vaccin
seed
viru
viru
isol
patient
sequenc
signific
differ
identifi
possibl
host
factor
advanc
age
case
year
old
autoimmun
diseas
system
lupu
erythematosu
rheumatoid
arthriti
case
potenti
immunosuppress
medic
may
administ
vaccin
two
case
although
autoimmun
diseas
recogn
risk
factor
warrant
attent
may
also
coincid
infect
contribut
diseas
unknown
agent
age
thymu
diseas
recogn
risk
factor
viscerotrop
diseas
higher
incid
yelavd
ica
peru
unexplain
nevertheless
current
recommend
use
yf
vaccin
chang
long
indic
use
adher
need
care
assess
risk
benefit
respect
age
rate
yeland
vari
differ
studi
undertaken
differ
popul
europ
uk
us
travel
limit
inform
advers
event
yeland
campaign
set
rate
yeland
vari
base
studypopul
observ
rang
per
studi
europ
us
discuss
dr
minor
emphas
explan
happen
peru
emphas
risk
viscerotrop
diseas
per
known
vaccin
dose
use
older
individu
known
thymu
diseas
risk
time
higher
total
case
viscerotrop
diseas
identifi
end
first
case
describ
brazil
case
identifi
retrospect
year
age
femal
child
case
viscerotrop
diseas
primari
vaccine
fatal
brazil
clearcut
age
distribut
million
infant
vaccin
everi
year
report
yelavd
associ
yf
vaccin
produc
russia
one
case
report
associ
yf
vaccin
produc
china
individu
previous
cancer
immunosuppress
may
predispos
yelavd
isol
advers
event
indistinguish
vaccin
viru
base
assay
use
peruvian
case
best
character
date
case
investig
gave
nonsignific
heterogen
sequenc
ident
report
sever
case
describ
clinic
genom
recov
virus
partial
fulli
sequenc
addit
studi
monkey
also
done
sever
yelavd
case
high
viremia
howev
may
depend
sampl
taken
time
taken
may
death
patient
also
exampl
high
antiyf
viru
immun
respons
case
need
standard
sampl
instanc
advers
event
group
discuss
whether
occurr
advers
event
follow
yf
vaccin
new
three
collect
yf
virus
total
wild
type
virus
three
vaccinerel
strain
identifi
one
isol
fatal
case
retrospect
found
virus
test
theiler
monkey
viscerotrop
cours
deriv
strain
question
whether
viscerotrop
test
describ
current
recommend
give
relev
data
must
address
addit
data
record
manufactur
test
undertaken
defin
minor
sequenc
chang
noncod
region
manufactur
seed
observ
signific
known
dr
barrett
utmb
observ
sequenc
chang
seed
us
strain
transfer
manufactur
consid
signific
significantli
amino
acid
substitut
wildtyp
asibi
vaccin
substrain
alway
conserv
viru
although
amino
acid
chang
characterist
dr
morag
ferguson
nibsc
summar
qualiti
safeti
issu
technic
specif
need
address
revis
recommend
current
recommend
seed
viru
state
identifi
histor
record
includ
inform
origin
substrain
method
attenu
passag
level
attenu
immunogen
demonstr
clinic
evalu
clear
strain
accept
whether
addit
test
molecular
method
includ
character
strain
would
use
recommend
state
master
work
seed
lot
yf
vaccin
viru
shall
shown
safe
immunogen
appropri
laboratori
test
includ
test
viscerotrop
immunogen
neurotrop
group
test
monkey
group
ask
whether
test
still
appropri
requir
previou
discuss
intern
associ
biolog
iab
symposium
conclud
seed
viru
low
score
consequ
good
control
viru
recommend
test
procedur
could
clarifi
minimum
potenc
specif
express
iu
per
dose
approv
ecb
addit
agre
chang
releas
specif
exist
vaccin
justifi
clinic
data
eg
transfer
product
one
manufactur
anoth
includ
specif
iu
mous
ld
need
upper
limit
potenc
also
discuss
gacv
meet
june
addit
need
thermal
stabil
test
consid
context
stabil
data
establish
expiri
date
discuss
group
agre
histor
record
chart
deriv
seed
viru
need
revisit
updat
diagram
publish
recent
one
susan
robertson
late
manufactur
ask
document
sourc
seed
passag
level
strain
passag
get
avian
leucosi
viru
alv
free
viru
viru
genealog
histor
record
chain
custodi
document
agre
product
specif
pathogen
free
spf
egg
achiev
manufactur
would
requir
suggest
molecular
test
includ
character
new
seed
also
report
studi
dr
levenbook
discuss
iab
meet
neurovirul
differ
seed
compar
howev
util
test
without
appropri
posit
control
question
passfail
criteria
establish
signific
result
obtain
clear
howev
test
one
possibl
measur
pathogen
includ
revis
recommend
upper
potenc
limit
yf
vaccin
defin
present
relationship
median
lethal
dose
ld
plaqu
form
unit
pfu
iu
variabl
main
justif
use
iu
establish
upper
potenc
limit
difficult
establish
clinic
trial
dr
barrett
comment
amount
viru
vaccin
gone
year
assay
vaccin
releas
specif
vari
current
shortag
vaccin
perhap
viru
content
dose
could
reduc
dose
could
produc
number
egg
howev
releas
end
shelflif
specif
may
differ
manufactur
relat
stabil
vaccin
also
note
discuss
publish
clinic
trial
data
use
either
plaqu
reduct
neutral
prnt
log
neutral
index
lni
measur
antibodi
level
comparison
difficult
dr
darci
hokama
biomanguinho
brazil
report
produc
present
yf
vaccin
prequalifi
compani
minimum
potenc
limit
log
iu
set
follow
consult
discuss
minimum
potenc
requir
rang
potenc
observ
vial
store
recommend
temperatur
log
iuhuman
dose
vial
rang
log
iuhuman
dose
log
iuhuman
dose
thermost
test
present
contain
differ
stabil
batch
mean
titr
log
iu
compani
consid
minimum
requir
endors
ecb
therefor
appropri
doserespons
trial
undertaken
biomanguinho
help
establish
upper
potenc
limit
four
thousand
batch
test
gener
safeti
test
failur
compani
recommend
omit
test
lot
releas
test
dr
hokama
also
present
data
molecular
detect
mycoplasma
instead
cultur
method
polymeras
chain
reaction
pcr
detect
method
valid
sampl
specif
sensit
limit
detect
pcr
method
use
approxim
coloni
form
unit
cfu
much
lower
cultur
method
current
yf
seed
strain
produc
deriv
secondari
seed
lot
use
work
seed
lot
four
vial
master
seed
remain
vial
secondari
seed
work
seed
lot
compris
vial
avail
last
year
assum
annual
product
million
dose
molecular
character
work
seed
lot
perform
biochemistri
molecular
biolog
depart
oswaldo
cruz
institutefiocruz
dr
ricardo
galler
full
genom
work
seed
lot
compar
genom
seed
lot
deriv
seed
viru
document
spf
egg
use
product
neurovirul
test
perform
seed
viru
lot
includ
refer
viru
work
seed
also
test
clinic
trial
without
evid
viscerotrop
discuss
note
pcrbase
mycoplasma
detect
test
discuss
european
pharmacopoeia
ep
dr
bing
zeng
cnbg
china
nation
biotech
group
report
yf
vaccin
market
china
sinc
new
plant
capac
million
dose
expect
oper
actual
product
approxim
dosesyear
vaccin
recommend
travel
china
seed
viru
origin
rockefel
institut
deriv
strain
master
seed
establish
passag
chick
embryo
seed
test
neurovirul
immunogen
requir
recommend
differ
minimum
level
potenc
test
mice
cell
name
log
ml
respect
howev
specif
given
product
insert
singl
human
dose
ml
contain
less
log
pfu
live
yellow
fever
viru
vaccin
shelflif
month
stabl
titr
log
product
new
facil
result
improv
vaccin
lower
ovalbumin
content
singl
dose
present
vaccin
prequalifi
function
chines
nra
yet
approv
nra
assess
may
request
viru
seed
product
would
result
new
product
discuss
dr
zeng
indic
viru
alv
free
product
spf
egg
sequenc
also
publish
dr
alexandra
sinyugina
chumakov
institut
russia
report
yf
vaccin
produc
sinc
russia
vaccin
prequalifi
spf
egg
use
sinc
facil
recent
renov
use
spf
egg
result
increas
harvest
titr
decreas
reject
rate
institut
hope
abl
extend
shelflif
month
work
seed
vaccin
prepar
primari
seed
master
work
seed
test
monkey
neurovirul
viscerotrop
test
viru
use
refer
standard
russian
standard
calibr
iu
minimum
titr
log
although
titr
gener
log
year
less
log
iu
dr
lionel
gerent
sanofi
pasteur
franc
report
compani
includ
inhous
standard
everi
assay
run
nibsc
code
parallel
test
indic
data
suggest
lose
potenc
mean
titr
ml
ml
user
observ
report
loss
potenc
nibsc
variabl
titr
higher
sanofi
standard
respect
log
compar
log
dr
gerent
consid
upper
potenc
limit
appropri
variabl
mean
titer
vaccin
anoth
howev
intern
upper
limit
essenti
followup
consist
product
consequ
suggest
intern
upper
limit
specif
yf
vaccin
ii
defin
manufactur
accord
trend
analysi
product
mean
titr
iudos
standard
deviat
iii
need
approv
nation
regulatori
author
dr
pascal
cottin
sanofi
pasteur
franc
describ
safeti
issu
investig
product
lot
produc
period
studi
includ
viral
plaqu
size
distribut
demonstr
consist
potenc
homogen
viral
popul
genet
stabil
revers
transcriptas
pcr
rtpcr
estim
total
viral
load
bulk
found
highli
homogen
studi
reinforc
robust
process
product
safeti
profil
stamaril
tm
qualiti
manufactur
investig
routin
conduct
sinc
specif
action
taken
stamaril
tm
date
investig
undertaken
case
seriou
advers
event
notif
involv
review
batch
record
nonconform
chang
technic
complaint
procedur
also
allow
possibl
evalu
retain
sampl
visual
physic
test
respect
yelavd
total
case
fatal
nonfat
report
pharmacovigil
databas
sanofi
pasteur
sinc
fatal
case
yelavd
spain
investig
regard
vaccin
qualiti
differ
evidenc
lot
vaccin
dose
analys
parallel
term
potenc
genom
titer
plaqu
size
profil
dr
nicola
boschetti
crucel
berna
switzerland
updat
group
develop
yf
vaccin
crucel
vaccin
current
licens
process
product
viru
strain
transfer
robert
koch
institut
rki
viru
grown
spf
egg
releas
specif
flavimun
log
pfudos
end
shelflif
specif
log
pfudos
ident
rki
relationship
establish
crucel
mous
ld
dose
pfudos
log
pfudos
genet
sequenc
vaccin
seed
viru
publish
anim
safeti
test
work
seed
lot
perform
includ
monkey
test
immunogen
viscerotrop
neurotrop
guinea
pig
adult
mice
test
extran
agent
guinea
pig
adult
mice
test
abnorm
toxic
done
three
consecut
manufactur
lot
gave
satisfactori
result
dr
antoin
diatta
institutpasteur
dakar
seneg
report
yf
vaccin
seneg
produc
sinc
use
strain
product
capac
million
dose
per
year
challeng
suppli
high
qualiti
safe
yf
vaccin
complianc
gmp
tr
recommend
spf
egg
sourc
germani
use
product
emphas
need
defin
good
minimum
potenc
thermal
stabil
test
import
vaccin
use
tropic
area
vial
master
seed
passag
produc
remain
limit
stock
work
seed
lot
produc
passag
increas
product
capac
new
work
seed
requir
dr
diatta
ask
whether
vaccin
batch
passag
could
use
vaccin
seed
lot
character
accord
tr
recommend
note
level
less
seed
passag
level
also
queri
laboratori
abl
undertak
anim
test
note
test
perform
limit
number
laboratori
would
less
variat
refer
strain
also
requir
train
staff
test
agre
upper
limit
potenc
document
queri
could
determin
addit
inform
requir
effect
increas
yf
titer
qualiti
safeti
vaccin
group
agre
clinic
data
requir
whatev
viru
use
new
seed
case
viscerotrop
diseas
occur
follow
use
institutpasteur
dakar
yf
vaccin
link
specif
vaccin
batch
identifi
may
previou
exposur
vaccine
flaviviru
antibodi
recipi
also
note
least
campaign
undertaken
vaccin
good
surveil
aefi
dr
sylvi
morgeaux
afssap
agenc
ais
de
sanitair
de
produit
de
franc
present
data
test
sanofi
pasteur
vaccin
manufactur
correct
factor
titer
ld
dose
titer
pfudos
log
correl
iu
pfu
afssap
log
iudos
log
pfu
afssap
calibr
inhous
standard
ih
iu
mean
valu
log
ml
mean
assay
perform
ml
obtain
collabor
studi
fiftytwo
batch
test
potenc
thermal
stabil
assay
inhous
standard
includ
titer
calcul
inhous
standard
log
iuhuman
dose
log
iuhuman
dose
similar
result
obtain
thermost
test
name
log
iuhuman
dose
ih
log
iuhuman
dose
afssap
continu
express
potenc
ld
european
pharmacopoeia
market
author
chang
use
ih
valid
assay
use
period
check
standard
deviat
ih
dr
morgeaux
note
look
stabl
assay
howev
note
declin
titr
vaccin
batch
rel
ih
discuss
manufactur
conclud
issu
vaccin
titr
standard
dr
guanmu
dong
nicpbp
nation
institut
control
pharmaceut
biolog
product
china
report
histori
monitor
advers
event
china
nation
advers
drug
reaction
report
system
initi
doctor
hospit
passiv
report
system
new
network
place
report
minor
side
effect
peacekeep
forc
go
sudan
peopl
immun
yf
vaccin
inactiv
je
vaccin
headach
fever
case
report
seriou
advers
event
yearold
american
chines
previous
rectal
cancer
chemotherapi
may
immunocompromis
patient
discharg
hospit
follow
recoveri
virolog
confirm
obtain
time
viru
seed
beij
strain
compar
refer
viru
strain
strain
share
homolog
publish
sequenc
genbank
databas
put
amino
acid
residu
beij
strain
e
protein
likelihood
revers
wildtyp
asibi
viru
isoleucin
threonin
may
associ
virul
specif
qualiti
improv
implement
chines
vaccin
lead
lower
content
ovalbumin
gdose
lower
amount
impur
singl
dose
vial
addit
test
residu
albumin
endotoxin
final
product
perform
candid
nation
refer
vaccin
prepar
twenti
three
thousand
ampoul
avail
titr
log
pfuml
ml
fill
coeffici
variat
residu
moistur
store
c
stabil
prepar
differ
temperatur
appear
good
need
calibr
china
would
like
develop
new
seed
lot
seed
vaccin
produc
new
seed
would
assess
clinic
trial
also
think
upper
limit
viru
titr
set
implement
dr
jurg
stalder
swissmed
switzerland
describ
result
viru
titrat
involv
year
period
omcl
biologika
mean
log
iuampoul
sd
assay
perform
swissmed
pfu
equal
iu
wherea
crucel
pfu
iu
despit
discrep
iu
batch
quit
similar
valu
differ
log
littl
loss
potenc
thermost
studi
dr
stalder
conclud
convers
pfu
iu
improv
compar
result
differ
laboratori
dr
maya
vorobieva
tarassevich
state
research
institut
russia
describ
studi
calibr
nation
standard
iu
correl
ld
pfu
rang
establish
pfu
iu
perform
assay
use
nation
standard
ns
russian
ns
titer
log
ml
rang
june
octob
rang
potenc
iu
routin
vaccin
batch
stabil
test
rang
minimum
potenc
specif
usual
express
iu
dr
vorobieva
agre
clinic
studi
import
establish
minimum
potenc
requir
thermost
test
data
indic
vaccin
stabl
also
comment
difficult
perform
test
monkey
difficult
get
suitabl
anim
far
case
viscerotrop
diseas
russian
vaccin
million
dose
administ
sinc
vaccin
use
russia
south
america
africa
dr
barrett
present
key
point
specif
yf
vaccin
need
consid
nonclin
section
includ
strain
viru
cite
suitabl
use
manufactur
yf
vaccin
whether
restrict
virus
alvfre
passag
historyrecord
genealog
vaccin
known
document
test
requir
master
seed
secondari
seed
vaccin
lot
need
review
genom
sequenc
determin
criteria
establish
whether
proceed
use
viru
prepar
seed
viru
amino
acid
substitut
degre
genet
heterogeneityst
use
rtpcr
also
review
biolog
viru
test
conduct
mice
nonhuman
primat
mosquito
consid
cell
cultur
assay
molecular
character
would
also
address
consider
given
whether
viru
strain
batch
vaccin
might
caus
neurotrop
viscerotrop
diseas
test
current
undertaken
nonhuman
primat
neurovirul
histopatholog
studi
viscerotrop
viremia
neuroinvas
assay
old
mice
new
small
anim
model
viscerotrop
develop
subsequ
publish
test
requir
could
cascad
assay
mosquito
compet
seed
viru
relev
amino
acid
substitut
cell
type
use
assay
whether
assess
plaqu
size
heterogen
use
consist
criterion
consid
discuss
note
produc
brazil
franc
switzerland
seneg
usa
use
strain
sequenc
central
databas
shown
good
homogen
agre
master
work
seed
includ
subsequ
work
seed
sequenc
use
inform
would
come
sequenc
vaccin
lot
suggest
high
number
amino
acid
chang
compar
consensu
sequenc
observ
mosquito
compet
test
undertaken
howev
nonhuman
primat
studi
laboratori
abl
perform
test
dr
mair
powel
mhra
medicin
healthcar
product
regulatori
agenc
uk
outlin
inform
need
clinic
section
document
includ
guidanc
compani
nra
specif
clinic
evalu
yf
vaccin
section
need
includ
consider
provis
clinic
data
support
major
chang
establish
manufactur
process
discuss
agre
recommend
revis
would
appli
live
attenu
vaccin
agre
approv
new
yf
vaccin
would
base
clinic
studi
safeti
immunogen
therefor
total
databas
would
allow
estim
possibl
risk
yeland
yelavd
preapprov
studi
addit
popul
studi
conduct
need
consider
ie
vaccin
naiv
previous
vaccin
individu
resid
endem
nonendem
area
studi
conduct
nonendem
area
restrict
consid
need
yf
vaccin
like
conduct
adult
present
travel
clinic
elderli
person
may
includ
travel
high
risk
area
contraind
vaccin
data
children
like
obtain
studi
endem
area
routin
vaccin
perform
accord
nation
region
recommend
like
inclus
children
age
month
would
possibl
desir
endem
countri
exclus
criteria
trial
would
includ
usual
contraind
receipt
live
attenu
vaccin
plu
individu
thymu
diseas
term
relev
past
experi
comment
brazil
studi
children
endem
area
done
adult
studi
demonstr
safeti
profil
accept
howev
nra
agre
specif
studi
children
requir
provid
studi
adult
satisfactori
approv
base
experi
use
vaccin
children
howev
effect
coadministr
mmr
children
evalu
clinic
studi
seem
like
practic
desir
end
part
discuss
group
agre
prefer
initi
studi
safeti
immunogen
undertaken
healthi
young
adult
yf
vaccin
resid
nonendem
area
subject
show
adequ
immun
respons
compar
safeti
profil
comparison
licens
yf
vaccin
would
expect
similar
find
would
obtain
endem
area
may
may
consid
necessari
obtain
experi
use
children
practic
reason
would
like
come
studi
endem
area
agre
dose
rang
studi
determin
minimum
potenc
requir
provid
adequ
immun
respons
would
valuabl
new
vaccin
base
seed
data
could
use
set
accept
end
shelflif
potenc
could
also
potenti
increas
vaccin
product
estim
minimum
initi
viru
titr
per
dose
studi
choic
compar
vaccin
depend
studi
object
case
wellestablish
licens
compar
may
select
accept
mani
nra
possibl
desir
compar
widespread
use
year
data
effect
avail
well
reliabl
descript
safeti
profil
howev
vaccin
manufactur
exist
seed
use
compar
studi
assess
vaccin
manufactur
new
seed
lot
group
agre
viru
neutral
assay
use
compar
immunogen
test
refer
vaccin
either
prnt
assay
lni
assay
accept
primari
comparison
base
geometr
mean
titr
gmt
appropri
accept
criteria
predefin
studi
protocol
howev
seroconvers
rate
revers
cumul
distribut
also
provid
review
compar
consist
gener
experi
gain
yf
vaccin
group
also
agre
flaviviru
hemagglutinin
inhibit
test
may
use
demonstr
individu
assess
viremia
routin
requir
usual
recipi
yf
vaccin
temporari
viremia
enhanc
safeti
surveil
undertaken
market
predefin
period
data
kept
review
accord
extent
experi
gain
ie
reflect
use
initi
postapprov
year
prefer
enhanc
safeti
surveil
involv
collabor
nation
author
brighton
collabor
case
definit
yelavd
event
use
describ
advers
event
avail
note
prepar
new
protocol
investig
seriou
advers
event
follow
yf
vaccin
hope
incid
yelavd
yeland
may
reduc
identif
factor
predispos
individu
reaction
also
aefi
associ
yelavd
yeland
may
quickli
identifi
lead
rapid
institut
adequ
manag
measur
meet
group
note
follow
addit
report
comment
dr
reinaldo
martin
biomanguinho
brazil
report
molecular
anim
test
well
clinic
trial
undertaken
new
seed
viru
lot
produc
gave
ident
result
secondari
seed
lot
use
sinc
batch
vaccin
associ
report
seriou
advers
reaction
peru
titr
pfudos
test
although
titr
releas
two
year
greater
indic
qualiti
problem
differ
manufactur
batch
compar
other
evid
current
pfu
dose
use
yf
vaccin
may
higher
need
achiev
accept
seroconvers
rate
exampl
volunt
given
pfu
sc
ii
volunt
given
pfu
sc
iii
volunt
given
pfu
sc
biomanguinho
therefor
initi
doserespons
studi
brazil
dose
rang
pfudos
pfudos
dr
nicola
boschetti
crucel
berna
switzerland
describ
bridg
studi
undertaken
yf
vaccin
follow
transfer
product
robert
koch
institut
crucel
vaccin
produc
strain
viru
stamaril
compar
vaccin
aim
studi
demonstr
noninferior
immun
respons
well
monitor
safeti
flavimun
shown
noninferior
yfv
rki
stamaril
regard
immunogen
signific
advers
event
observ
genet
stabil
crucel
vaccin
demonstr
sequenc
viru
isol
vaccin
recipi
amplif
e
protein
gene
subject
sequenc
analysi
demonstr
virus
ident
vaccin
viru
dr
teyssou
sanofi
pasteur
franc
describ
sanofi
pasteur
experi
stamaril
variou
studi
undertaken
vaccin
lot
viru
seed
sinc
januari
case
classifi
yelavd
yeland
report
stamaril
initi
develop
sanofi
pasteur
address
potenti
safeti
concern
preclin
studi
undertaken
retrospect
archiv
bulk
lot
deriv
secondari
seed
lot
produc
test
consensu
sequenc
analysi
plaqu
size
phenotyp
compar
publish
sanofi
pasteur
sequenc
four
nucleotid
substitut
present
secondari
seed
lot
conserv
product
batch
incid
aminoacid
level
plaqu
phenotyp
studi
detect
phenotyp
differ
popul
differ
observ
potenc
lot
also
test
rtpcr
determin
viral
load
also
consist
data
reinforc
stabil
viru
use
manufactur
stamaril
sanofi
produc
new
seed
sequenc
futur
analysi
seed
lot
need
develop
new
model
monitor
viscerotrop
neurotrop
dr
teyssou
consid
new
work
seed
develop
clinic
trial
need
provid
bridg
character
studi
perform
mutat
master
work
seed
lot
observ
import
know
whether
mutat
lead
phenotyp
alter
affect
immunogen
group
review
main
point
discuss
agre
key
chang
scope
revis
current
recommend
name
section
gener
consider
includ
refer
yeland
yelavd
genealog
diagram
publish
also
review
updat
appropri
product
qualiti
assess
express
vaccin
viru
titr
iu
specifi
use
spf
egg
monkey
test
transfer
nonclin
section
monkey
test
remain
current
written
transfer
appendix
dose
use
monkey
equival
human
dose
preclin
assess
includ
viru
histori
identifi
genealog
diagram
master
work
seed
sequenc
addit
seed
character
anim
plaqu
test
demonstr
consist
consider
given
inclus
requir
manufactur
upper
limit
potenc
depend
clinic
experi
product
clinic
section
detail
clinic
trial
need
includ
new
master
seed
even
prepar
seed
maximum
allow
level
passag
master
seed
work
seed
work
seed
product
limit
one
pass
respect
new
work
seed
passag
previous
clinic
trial
requir
specif
exampl
consider
present
discuss
ip
dakar
wish
prepar
new
master
seed
one
passag
current
master
seed
work
seed
one
passag
instanc
would
appropri
clinic
trial
comparison
old
new
vaccin
biomanguinho
prepar
new
master
one
passag
egg
new
work
seed
clinic
trial
immunogen
safeti
complet
publish
gave
satisfactori
result
crucel
use
yf
vaccin
seed
viru
make
master
work
seed
clinic
trial
undertaken
china
three
passag
master
work
seed
group
inform
ep
state
one
passag
level
master
work
seed
group
agre
process
revis
focus
updat
current
recommend
complet
rewrit
